Primary Membranous Nephropathy Study

Primary Membranous Nephropathy Trials in Phoenix

Aventiv Research is currently participating in a primary membranous nephropathy study at our Phoenix, AZ location. Primary membranous nephropathy (pMN) is a kidney-specific, autoimmune disease. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Primary Membranous Nephropathy Clinical Trial

The primary objective of this study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of obinutuzumab as compared to tacrolimus, two FDA approved drugs, in patients with pMN. This is an open-label study, patients will get either obinutuzumab or tacrolimus. You maybe be eligible to participate in this study if you:

  • Are 18 to 75 years of age
  • Have a diagnosis of pMN according to renal biopsy prior to or during screening

Hyperkalemia Study

Hyperkalemia Trials in Phoenix

Aventiv Research is currently participating in a hyperkalemia study at our Phoenix, AZ location. Hyperkalemia is the medical term that describes a potassium level in your blood that’s higher than normal. Potassium helps your nerves and muscles, including your heart, work the right way. In the early stages of kidney disease, the kidneys can often make up for high potassium. But as kidney function gets worse, they may not be able to remove enough potassium from your body. Advanced kidney disease is a common cause of hyperkalemia. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Hyperkalemia Clinical Trial

The primary objective of this study is to evaluate the safety and pharmacodynamics of an investigational drug in different dose combinations to identify the best dose combination for further evaluation. The study will also assess the safety and efficacy of a 4-week treatment of the investigational drug at the optimal dose combination in patients with hyperkalemia. You maybe be eligible to participate in this study if you:

  • Are 18 to 85 years of age
  • Have chronic kidney disease
  • Have high potassium levels in your blood (hyperkalemia) between 5.1 to <6.5 mmol/L at screening

Polycystic Kidney Disease Study

Polycystic Kidney Disease Trials in Phoenix

Aventiv Research is currently participating in a polycystic kidney disease study at our Phoenix, AZ location. Polycystic kidney disease (PKD) is a genetic disorder that causes cysts to grow in the kidneys, where they can disrupt functioning. Health complications include high blood pressure and kidney failure. Most people with PKD will eventually need dialysis or a kidney transplant. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Polycystic Kidney Disease Clinical Trial

The objective of this study is to study the efficacy and safety of an investigational drug against placebo in adults with autosomal dominant polycystic kidney disease (ADPKD). You maybe be eligible to participate in this study if you:

  • Are 18 to 70 years of age
  • Have a diagnosis of autosomal dominant polycystic kidney disease (ADPKD)

Hyperoxaluria Study

Hyperoxaluria Trials in Phoenix

Aventiv Research is currently participating in a hyperoxaluria study at our Phoenix, AZ location. Hyperoxaluria refers to a large amount of oxalate in the urine. Too much oxalate in the urine can lead to build-up of calcium oxalate crystals in the kidneys and urinary tract, which can lead to kidney stones, decreased kidney function, and even kidney failure. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Hyperoxaluria Clinical Trial

The objective of this study is to determine the efficacy and durability of an investigational drug against placebo in reducing urinary oxalate excretion in subjects with enteric hyperoxaluria. The study will also evaluate the long-term safety and treatment of the investigational drug against placebo on kidney stone disease progression and kidney function. You maybe be eligible to participate in this study if you:

  • Are at least 18 years of age
  • Have an underlying enteric disorder associated with malabsorption such as:
    • malabsorptive bariatric surgery a minimum of 12 months prior to screening
    • inflammatory bowel disease with small bowel involvement
    • short bowel syndrome
    • or other malabsorption syndrome with known or suspected history of history of calcium oxalate kidney stones or oxalate nephropathy
  • Have had at least one documented kidney stone within 2 years prior to screening

Note: people who have had restrictive-only bariatric procedures (i.e vertical banded gastroplasty, adjustable gastric banding, sleeve gastrectomy) are not eligible to participate in the study.

Obesity with Type 2 Diabetes

Obesity Trials in Dublin, Ohio

Aventiv Research is currently participating in a obesity study at our Dublin, Ohio location. Obesity affects more than one-third of adults in America and results from an energy imbalance where the amount of calories consumed are greater than the amount of calories expelled. This can be caused by genetics, eating habits, location, and well-being. Individuals who are obese are more likely to suffer from type 2 diabeteshypertension, certain types of cancer and more. In addition to being life-altering and potentially fatal, these conditions put individuals at an increased risk of developing cardiovascular disease.

Enroll Now

Obesity with Type 2 Diabetes Study

The primary objective of this study is to evaluate the efficacy and safety of an investigational drug compared to placebo on the maintenance of weight loss in study participants who have Type 2 Diabetes, and have obesity or are overweight. You may qualify for our obesity study if:

  • You are at least 18 years of age
  • Have type 2 diabetes
  • Have a history of at least one self-reported unsuccessful dietary effort to lose body weight
  • Have a BMI of ≥27 kg/m2

Ticagrelor Reversal Study

Ticagrelor Reversal Study in Columbus, OH

Aventiv Research in Columbus is currently enrolling healthy volunteers for a phase 1 clinical trial at our Columbus, Ohio location to study an investigational drug to reverse the effects of another drug called ticagrelor. Ticagrelor (also called Brilinta®) is an approved drug used to help reduce clotting of your blood. A reversal drug helps restore blood’s ability to form clots which is very important if there is life threatening bleeding or serious injury.

Enroll Now

Ticagrelor (Brilinta®) Reversal Study

The primary objective of this clinical trial is to demonstrate reversal of the antiplatelet effects of ticagrelor with an investigational intravenous drug vs. placebo. This research study will require you to visit Aventiv Research for five consecutive overnight stays as well as subsequent follow up visits.

Qualified participants must be:

  • In general good health and well-controlled existing medical conditions
  • Male or female between 50-80 years old
  • Willing to take daily Aspirin 81 mg

Patients potentially may not qualify if they:

  • They have had a significant acute illness, medical/surgical procedure, or trauma within 4 weeks of the administration of study drug
  • Have any planned surgical procedure within the next 2 months
  • Are unable to stay in-house during the specified periods

COVID-19 Vaccine Study

COVID-19 Vaccine Trials in Columbus

Aventiv Research is currently participating in an investigational COVID-19 vaccine study at our Columbus, Ohio location. We are currently enrolling healthy adults who are 18-65 years old to better understand the potential safety and efficacy of the vaccine.

Enroll Now

COVID-19 Vaccine Study

The primary objective of this clinical trial is to evaluate the safety, tolerability, immunogenicity, and potential efficacy of a CoVLP formulation, compared to placebo, against COVID-19 in adults.

We are specifically looking for volunteers who are:

  • Adults 18-64 years of age who are overtly healthy as determined by medical evaluation

As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.

AstraZeneca COVID-19 TACKLE Treatment Study

COVID-19 Treatment Trials in Columbus

Aventiv Research is currently participating in an investigational COVID-19 treatment study at our Columbus, Ohio location. We are currently enrolling adults who have tested positive for COVID-19 within the last three days.

Enroll Now

AstraZeneca COVID-19 TACKLE Study

The primary objective of this clinical trial is to estimate the efficacy of an investigational drug compared to placebo for the treatment of COVID-19 in adults with mild to moderate symptoms of COVID-19. You may be eligible to participate if you meet the following criteria:

  • You are  at least 18 years old
  • Have a laboratory-confirmed SARS-CoV-2 infection, as determined by a antigen or nucleic acid test collected no more than 3 days before starting the trial
  • You are currently not hospitalized
  • You have one or more of the following symptoms:
    • Subjective fever or feeling feverish
    • Cough
    • Shortness of breath or difficulty breathing at rest or with activity
    • Sore throat
    • Body pain or muscle pain/aches
    • Fatigue
    • Headache
    • Chills
    • Nasal obstruction or congestion
    • Nasal discharge
    • New loss of taste or smell
    • Nausea or vomiting
    • Diarrhea
    • New onset confusion (only for participants at least 60 years old)
    • Appetite loss or decreased food intake (only for participants at least 60 years old)
    • Increased supplemental oxygen requirement (only for participants on baseline supplemental oxygen)

As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.

Birth Control Study

Contraceptive Trials at Aventiv Research Women’s Health

Aventiv Research is currently enrolling participants for a birth control study at our Women’s Health location in Columbus, Ohio.

Enroll Now

Birth Control Pill Study

The primary objective of this study is to test how well an investigational birth control pill works to prevent pregnancy and which side effects it causes. You may qualify for this study if:

  • You are female between the ages of 13-45 years old
  • Are sexually active, postmenarcheal and premenopausal, and at risk of pregnancy
  • You have never used hormonal contraceptives before, or
  • You have used hormonal contraceptives in the past, but have had a hormonal contraceptive-free period before joining the study and a full menstrual cycle during the drug-free period, or
  • You directly switch from another hormonal contraceptive (switchers).

NASH Ambition Study

NASH Trials in Columbus

Aventiv Research is currently participating in the NASH Ambition study at our Columbus, Ohio location. NASH (Non-Alcoholic SteatoHepatitis) is the form of liver disease that is triggered by what has come to be known as the “Western diet”, characterized especially by high-fat, high-sugar, and processed foods. Among the effects of a prolonged Western diet is fat accumulation in liver cells (steatosis) which is described as Non-Alcoholic Fatty Liver Disease (NAFLD) and can predispose cells to injury.

People who develop NASH often have additional predisposing conditions such as diabetes and hypertension, but the exact biochemical events that trigger and maintain the progression are not well known. Many people in the early stages of disease do not have significant symptoms and therefore do not know that they have it.  Advances in drug therapy are key to treating this disease at its early stages and preventing further liver damage.

Enroll Now

NASH Ambition Study

The primary objective of the NASH Ambition clinical study is to evaluate the safety and tolerability of an investigational drug in presumed nonalcoholic steatohepatitis (NASH) fibrosis stage 2
(F2)/fibrosis stage 3 (F3) patients compared to placebo. You may be eligible to participate if you:

  • Are 18 – 75 years old
  • Have been diagnosed of NASH
  • Cannot have known non-NASH liver diseases including:
    • Autoimmune diseases
    • Alcoholic liver disease
    • HIV
    • Active Hepatitis B or C

We now offer individuals with known risk factors of Non-Alcoholic Fatty Liver Disease (NAFLD) a free Fibroscan screening.